Pancreatic Pseudocyst Drainage — Procedure Guide, Recovery & Risks | MyMedicPlus

A pancreatic pseudocyst is a fluid collection arising after acute or chronic pancreatitis, or after pancreatic ductal trauma, enclosed in a non-epithelialised fibrous wall -- distinguishing it from true pancreatic cysts (serous cystadenoma, intraductal papillary mucinous neoplasm, IPMN) which have an epithelial lining. The collection develops when disruption of the pancreatic duct -- from inflammatory injury, calculi, or blunt abdominal trauma -- allows enzyme-rich pancreatic juice to leak into the peripancreatic space, accumulating and becoming walled off by a reactive fibrous tissue response over 4-6 weeks. The defining pathological feature is absence of an epithelial lining; the wall is composed entirely of fibrous and granulation tissue.

The fluid within a pseudocyst contains high concentrations of pancreatic enzymes (amylase activity typically exceeding 1,000 IU/L -- many times higher than serum levels), necrotic debris, haemoglobin breakdown products, and inflammatory exudate. Pseudocysts are distinguished from walled-off necrosis (WON) -- a more complex collection containing substantial solid necrotic pancreatic or peripancreatic tissue -- arising later in severe necrotising pancreatitis and requiring more involved endoscopic or surgical debridement.

Pancreatic pseudocysts form in approximately 10-15% of acute pancreatitis episodes, with the highest incidence (30-40%) after severe necrotising pancreatitis. In chronic pancreatitis, they occur in 20-40% of patients due to repeated inflammatory episodes and ductal hypertension from strictures or calculi causing upstream duct dilatation and rupture. The majority of pseudocysts arising after mild acute pancreatitis resolve spontaneously within 4-6 weeks -- particularly those under 6 cm without symptoms or complications -- without requiring intervention. Larger, symptomatic, or complicated pseudocysts require drainage.

Endoscopic ultrasound (EUS)-guided transmural drainage with lumen-apposing metal stents (LAMS) is now the first-line treatment at expert centres, achieving technical success in 90-95% of cases and superseding surgical cystenterostomy and percutaneous drainage as the preferred primary modality for accessible pseudocysts with adequate cyst-stomach wall apposition on EUS.

Drainage of a pancreatic pseudocyst is indicated for symptomatic pseudocysts causing persistent abdominal pain, early satiety, nausea, biliary obstruction from compression of the common bile duct, or weight loss affecting nutritional status. Pseudocysts that are enlarging on serial CT or MRI imaging over 4–6 weeks, or that develop complications including secondary infection (forming a walled-off necrosis or infected pseudocyst), haemorrhage into the cyst cavity, or rupture causing ascites or pleural effusion, require urgent drainage. Asymptomatic pseudocysts that are stable in size (under 6 cm, no complications) are managed conservatively with imaging surveillance every 4–6 weeks — spontaneous resolution occurs in 30–40% of post-acute pancreatitis pseudocysts. Absolute contraindications to endoscopic drainage include inadequate apposition between the cyst wall and the gastrointestinal lumen (over 1 cm gap on EUS), significant intervening blood vessels, and coagulopathy uncorrected before the procedure.

Endoscopic ultrasound (EUS)-guided transmural drainage is now first-line. A lumen-apposing metal stent (LAMS) is placed through the stomach or duodenum wall into the pseudocyst under EUS guidance, creating a fistula for drainage. Surgical cystgastrostomy or cystjejunostomy is reserved for EUS-inaccessible cysts. Percutaneous drainage treats infected collections. Endoscopic ultrasound (EUS)-guided transmural drainage is now first-line. A lumen-apposing metal stent (LAMS) is placed through the stomach or duodenum wall into the pseudocyst under EUS guidance, creating a fistula for drainage. Surgical cystgastrostomy or cystjejunostomy is reserved for EUS-inaccessible collections or when endoscopic drainage fails. Percutaneous CT- or ultrasound-guided drain placement is used for infected collections or when EUS is unavailable. After LAMS placement, the stent is removed at 4–6 weeks after imaging confirmation of cyst resolution. Necrosectomy via the LAMS — direct endoscopic necrosectomy (DEN) — is performed for walled-off necrosis with solid debris, using irrigation catheters and instruments through the stent lumen. Multiple sessions may be required for large necrotic collections. Nasocystic drainage catheters through the LAMS allow irrigation of complex necrotic collections. Hydrogen peroxide diluted irrigation via the stent can facilitate debridement of organised debris during DEN sessions. ERCP with pancreatic duct stenting addresses upstream duct obstruction contributing to cyst formation, reducing recurrence after drainage.

EUS-guided drainage with LAMS achieves technical success in 90–95% of cases and clinical resolution (cyst collapse on imaging and symptom resolution) in 80–90% at 3 months. Endoscopic drainage avoids general anaesthesia and surgical recovery in most patients. For walled-off necrosis — a more complex collection containing solid necrotic debris — direct endoscopic necrosectomy through the LAMS achieves clearance in 80–90% with multiple sessions. Surgical internal drainage (cystjejunostomy) achieves long-term resolution in 85–90% of cases and is preferred for pseudocysts communicating with the main pancreatic duct in patients with chronic pancreatitis, where endoscopic drainage alone has high recurrence rates. EUS-guided drainage with LAMS achieves technical success in 90–95% of cases and clinical resolution (cyst collapse on imaging and symptom resolution) in 80–90% at 3 months. Endoscopic drainage avoids general anaesthesia and surgical recovery in most patients. For walled-off necrosis — a more complex post-pancreatitis collection — step-up approach (percutaneous drainage first, then minimally invasive necrosectomy only if needed) reduces organ failure and mortality compared to immediate open surgical necrosectomy (PANTER trial). Surgical cystgastrostomy achieves durable drainage with low recurrence in carefully selected cases.

EUS-guided LAMS drainage risks include haemorrhage from transgastric or transduodenal puncture (2–5% minor bleeding; under 1% requiring intervention), perforation (under 2%), secondary infection of the pseudocyst cavity if not adequately drained, stent migration into the cyst or gastrointestinal lumen, stent occlusion requiring repeat endoscopy, and pseudocyst recurrence in 10–15% if an underlying pancreatic duct communication is not treated. Buried LAMS syndrome — overgrowth of tissue over the intragastric flange of the stent — occurs if stents are left in place longer than 4 weeks and may require endoscopic laser or argon plasma coagulation for removal. Surgical cystjejunostomy carries higher operative risks including anastomotic leak, wound infection, and ileus, with longer recovery, but provides more durable drainage and lower recurrence for large or chronic pseudocysts.

After EUS-guided LAMS drainage, patients are typically hospitalised for 2–5 days to monitor drain function, initiate oral diet, and confirm cyst decompression on cross-sectional imaging at 24–48 hours. Oral fluids are started the day of the procedure and diet advanced as tolerated. Proton pump inhibitor therapy is prescribed to protect the gastric mucosa during endoscopic drainage. LAMS stents are removed at 4–8 weeks once the pseudocyst has collapsed on CT or MRI; early removal prevents buried stent syndrome. Alcohol cessation is mandatory and permanent if the pseudocyst arose from alcohol-related pancreatitis. A low-fat diet during the recovery period reduces exocrine pancreatic stimulation. Pancreatic enzyme replacement therapy is initiated if exocrine insufficiency has developed from underlying chronic pancreatitis. Serial CT or MRI monitoring at 4–6 weeks, then 3 months, confirms cyst resolution and identifies recurrence.